Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?

Company Overview - Aptevo Therapeutics Inc. (APVO) is part of the Medical group, which is currently ranked 1 within the Zacks Sector Rank, encompassing 1011 companies [2] - The company has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Metrics - Year-to-date, Aptevo Therapeutics Inc. has gained approximately 15.6%, while the average loss in the Medical group is about 3.9%, demonstrating strong relative performance [4] - The Zacks Consensus Estimate for APVO's full-year earnings has increased by 65.1% over the past three months, reflecting improved analyst sentiment [3] Industry Context - Aptevo Therapeutics Inc. operates within the Medical - Biomedical and Genetics industry, which includes 513 companies and is currently ranked 63 in the Zacks Industry Rank [5] - The Medical - Biomedical and Genetics industry has experienced an average loss of 12.6% this year, further highlighting APVO's superior performance [5] Comparison with Peers - Another outperforming stock in the Medical sector is Accuray (ARAY), which has increased by 7.6% year-to-date and also holds a Zacks Rank of 2 (Buy) [4][6] - Accuray's EPS consensus estimate has surged by 200% over the past three months, indicating strong growth potential [5]